Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Research & Development: 2020-2025

Historic Research & Development for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $7.5 million.

  • Xeris Biopharma Holdings' Research & Development rose 27.09% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 13.67%. This contributed to the annual value of $25.6 million for FY2024, which is 14.41% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Research & Development stood at $7.5 million, which was down 7.10% from $8.1 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Research & Development's 5-year high stood at $10.1 million during Q4 2021, with a 5-year trough of $3.7 million in Q2 2022.
  • In the last 3 years, Xeris Biopharma Holdings' Research & Development had a median value of $6.1 million in 2024 and averaged $6.5 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Research & Development surged by 97.30% in 2021 and then slumped by 50.85% in 2022.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Research & Development stood at $10.1 million in 2021, then tumbled by 50.85% to $5.0 million in 2022, then increased by 28.80% to $6.4 million in 2023, then declined by 4.54% to $6.1 million in 2024, then increased by 27.09% to $7.5 million in 2025.
  • Its Research & Development was $7.5 million in Q3 2025, compared to $8.1 million in Q2 2025 and $7.8 million in Q1 2025.